DE3024305C2 - - Google Patents

Info

Publication number
DE3024305C2
DE3024305C2 DE3024305A DE3024305A DE3024305C2 DE 3024305 C2 DE3024305 C2 DE 3024305C2 DE 3024305 A DE3024305 A DE 3024305A DE 3024305 A DE3024305 A DE 3024305A DE 3024305 C2 DE3024305 C2 DE 3024305C2
Authority
DE
Germany
Prior art keywords
long
haloperidol
general formula
formula
bromperidol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3024305A
Other languages
German (de)
English (en)
Other versions
DE3024305A1 (de
Inventor
Carlos Deurne Be Niemegeers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE3024305A1 publication Critical patent/DE3024305A1/de
Application granted granted Critical
Publication of DE3024305C2 publication Critical patent/DE3024305C2/de
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19803024305 1979-06-28 1980-06-27 Parenteral verabfolgbares psychotropes arzneipraeparat mit langzeitwirkung Granted DE3024305A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8082679A JPS568318A (en) 1979-06-28 1979-06-28 Non oral long acting composition of haloperidol and bromperidol derivative

Publications (2)

Publication Number Publication Date
DE3024305A1 DE3024305A1 (de) 1981-01-22
DE3024305C2 true DE3024305C2 (enExample) 1989-12-07

Family

ID=13729223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19803024305 Granted DE3024305A1 (de) 1979-06-28 1980-06-27 Parenteral verabfolgbares psychotropes arzneipraeparat mit langzeitwirkung

Country Status (9)

Country Link
JP (1) JPS568318A (enExample)
BE (1) BE883994A (enExample)
CY (1) CY1255A (enExample)
DE (1) DE3024305A1 (enExample)
FR (1) FR2460932A1 (enExample)
GB (1) GB2054371B (enExample)
HK (1) HK83384A (enExample)
KE (1) KE3427A (enExample)
NL (1) NL190775C (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621892D0 (en) * 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
CA2269328A1 (en) 1996-10-31 1998-05-07 Richard B. Rothman Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use as noncompetitive antagonists of dopamine reuptake
RU2178297C1 (ru) * 2001-02-02 2002-01-20 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая антипсихотическим и противорвотным действием, и способ ее получения
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN107935983A (zh) 2008-10-03 2018-04-20 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂
PL2685979T3 (pl) 2011-03-18 2017-02-28 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113117092A (zh) * 2020-01-14 2021-07-16 中国科学院上海药物研究所 一种非水缓释递药系统
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408356A (en) * 1965-08-31 1968-10-29 Squibb & Sons Inc Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like
DE1695194A1 (de) * 1966-07-11 1971-03-18 Hoffmann La Roche Verfahren zur Herstellung von Piperidinderivaten
US3850935A (en) * 1971-10-16 1974-11-26 Sumitomo Chemical Co Process for producing piperidine derivatives by degrading quaternary piperidinium salts

Also Published As

Publication number Publication date
GB2054371A (en) 1981-02-18
JPS568318A (en) 1981-01-28
GB2054371B (en) 1983-08-03
FR2460932B1 (enExample) 1984-11-16
BE883994A (fr) 1980-12-29
NL190775B (nl) 1994-03-16
HK83384A (en) 1984-11-09
CY1255A (en) 1984-08-31
NL8003583A (nl) 1980-12-30
FR2460932A1 (fr) 1981-01-30
NL190775C (nl) 1994-08-16
DE3024305A1 (de) 1981-01-22
KE3427A (en) 1984-08-10

Similar Documents

Publication Publication Date Title
DE3024305C2 (enExample)
DE60030883T2 (de) Verfahren zur herstellung von alfentanil, sufentanil und remifentanil
EP0088274B1 (de) Neue 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihrer Verwendung in Arzneimitteln
EP0103796B1 (de) Neue Dihydropyrimidine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln
DE1770565C3 (de) S-Oxo^-carboxamidomethyl^dihydro-l,4-benzoxazin und pharmazeutische Mittel, enthaltend diese Verbindung
DE2065636C3 (de) Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2117572A1 (de) Unsymmetrische 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel II
DE2210672B2 (de) N-substituierte unsymmetrische 1 ^Dihydropyridinj^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2555590A1 (de) 1-substituierte-4-benzylidenpiperidine und verfahren zu ihrer herstellung
DE2407115A1 (de) Neue 1,4-dihydropyridinderivate
DE3031791C2 (enExample)
DD147537A5 (de) Verfahren zur herstellung von 1,2,4,5-tetra-alkyl-4-aryl-piperidinen
EP0010130A1 (de) Sila-substituierte 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung, Arzneimittel und Verfahren zu deren Herstellung
EP0717036B1 (de) Verwendung von 5-Acyl-1,4-dihydropyridin zur Bekämpfung der Erkrankungen des ZNS
EP0770082B1 (de) Dioxo-thiopyrano-pyridin-carbonsäure-derivate und ihre verwendung als arzneimittel
DE1620007C3 (de) Decahydroisochinoline
DE1938512C3 (de) Aminopiperidinderivate, Verfahren zu ihrer Herstellung und die Derivate enthaltende Arzneimittel
DE3028064C2 (enExample)
DE3142559A1 (de) "pyrimidin-derivate"
DE2242787C2 (de) 4-Phenyl-6-amino-3,4-dihydropyridon-(2)-3,5-dicarbonsäure-diäthylesterderivate, ein Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE1792764C3 (de) Coronarmittel
DE2528194C2 (de) Benzhydryloxyäthylamin-Derivate, deren Salze, Verfahren zur Herstellung derselben und solche enthaltende Arzneimittel
DE1620746A1 (de) Verfahren zur Herstellung von Phenothiazin-Derivaten
DE2550395C3 (de) lO.ll-Dihydro-S-carboxycyproheptadin
EP0049494B1 (de) Ester von 7-Hydroxylalkyl-1,3-dimethylxanthinen, Verfahren zu ihrer Herstellung und ihre Verwendung als lipidsenkende Mittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: C07D211/44

8128 New person/name/address of the agent

Representative=s name: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P.,

D2 Grant after examination
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN